Cumulated US Biotech Venture Capital Funding exceeds total volume of 2020 already in the third quarter of 2021

With a volume of roughly USD 24bn, US biotech companies have already raised more venture capital in the first three quarters of 2021 than in the whole year 2020 (USD 22.4bn). Compared to the first three quarters of 2020, the funding volume increased by 38%.

The largest transaction in the 3rd quarter amounted to USD 440m in Laronde Inc.

About FCF Life Sciences

FCF Life Sciences advises leading healthcare companies in Europe on financing transactions (equity, debt, and licensing) with regional and international investors. Our team consists of science-driven industry and finance experts with a strong track record in managing financing processes. We thrive to maximize the efficiency in the fundraising process and increase its closing probability.

Learn more about FCF Life Sciences, click here.

We closely track the activity in the financial markets and are passionate about capital markets research. Not every idea or research question make it into the final selection for our publications. However, we generate interesting information on financing trends in Life Sciences sector, which we would like to share in our blog.

To hear from us on the latest insights, please sign up here: